Boston scientific watchman flx™ left atrial appendage closure device demonstrates superior bleeding risk reduction to oral anticoagulation following a cardiac ablation in the option clinical trial

Data also demonstrates that the stroke risk reduction device is as effective as oral anticoagulants for patients with atrial fibrillation following a cardiac ablation marlborough, mass. and chicago , nov. 16, 2024 /prnewswire/ -- boston scientific corporation (nyse: bsx) today announced positive three-year primary endpoint results from the option global clinical trial of the watchman flx™ left atrial appendage closure (laac) device.
BSX Ratings Summary
BSX Quant Ranking